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Background.Theobjectiveswere(i)toevaluatetheimpactofacutepulmonarytuberculosis(PTB)andanti-TBtherapyontherela-
tionship between AST, ALT, and GGT levels in absence of conditions related to hepatotoxicity; (ii) to evaluate the rate and the time
of alterations of AST, ALT, and GGT. Design and Methods. A prospective followup of 40 adults (21 males; mean age of 34.7 ± 5.8
years) with active PTB on initial phase and continuation phase anti-TB.Results.O n l y3 %( n = 1) developed a transient and benign
ADRatday30withoutinterruptionofanti-TBtreatment.Withinnormalranges,GGTdecreasedsigniﬁcantlyfromday0today60,
whileASTandALTincreasedsigniﬁcantlyandrespectively.Duringday0–day60,therewasasigniﬁcant,negative,andindependent
association between GGT and AST. Conclusion. The initial two months led to signiﬁcant improvement of oxidative stress. Values
of oxidative markers in normal ranges might predict low rate of ADR.
1.Background
The concept of biomarkers is very important in this paper.
The role of biomarkers is now exponentially increasing in
guiding decisions in drug development and personalized
medicine.Abiomarkerisnotpredictiveorcasualtoadisease,
but it can predict patients’ response to compound by identi-
fying certain patient groups that are more likely to response
to the drug therapy or to avoid speciﬁc adverse events [1].
In patients with pulmonary tuberculosis (PTB), a signif-
icant improvement in oxidative stress and suppression of in-
ﬂammatory response have been recently reported after
the initial two-month therapy [2]. However, the literature
showed that even after six months of successful chemother-
apy, PTB is still associated with increased levels of circulating
lipid peroxides and low plasma concentrations of antioxi-
dants such as vitamin E [2, 3].
Before chemotherapy, Mycobacteria induce reactive oxy-
gen species (ROS) production by activating both mononu-
clear and polymorphonuclear phagocytes. Tuberculosis is,
therefore, characterized by poor antioxidants defence that
exposes to oxidative host tissue damage [3, 4]. Yasuda et al.
found that more than 50% of 113 PTB cases with nor-
mal liver function on admission showed abnormalities of
transaminases that were aggravated up to 4th week after ad-
ministration of drugs, and 80% up to the 8th week [5].
Almost 33% of the world population infected withMyco-
bacterium tuberculosis live in developing countries including
Brazzaville, the Republic of Congo [6]. Anti-PTB drug-
related adverse reactions [7] include benign or fatal hepatic
transaminase elevation without any intervention [8, 9].
WorldHealthOrganization(WHO)establishedamajorstra-
tegy of directly observed treatment short course (DOTS),
which is adopted by the Republic of Congo, our country.2 Advances in Pharmacological Sciences
The potentially hepatotoxic anti-TB drugs from the ﬁrst-line
regimen are isoniazide, rifampicin, and pyrazinamide [10].
The following conditions increase the risk of anti-TB
drug-induced hepatitis: malnutrition, excessive alcohol in-
take, aging, chronic hepatic diseases including viral infec-
tions (HBV, HCV, and HIV/AIDS), female sex, ethnicity
(Asians),concurrentadministrationofenzymeinducers,and
inadequate compliance [7, 9, 11, 12].
1.1. Rationale. There are no data related to the chronological
observation of liver enzymes and adverse drug reactions
(ADR) in PTB patients. This information is useful to deter-
mine whether or not the antituberculosis drugs should be
discontinued when hepatic dysfunction occurs. Indeed,
Yasuda et al. showed that cases with higher peak values
and exacerbation in transaminases had a tendency-delayed
normalization [5].
With the current and increasing interest in oxidative
stress [3], emphasis is to develop functional biomarkers of
oxidative stress with epidemiological and clinical implica-
tions such as gamma-glutamyltransferase (GGT) [13–15]
and alanine aminotransferase (ALT) [15], except for aspar-
tate aminotransferase (AST) [14]. Therefore, the ﬁrst objec-
tive of this study was to evaluate the impact of acute pul-
monary tuberculosis (PTB) and anti-TB therapy on the re-
lationship between AST, ALT and GGT levels in absence of
conditions related to hepatotoxicity. The second objective of
the study was to evaluate the rate and the time, pattern of
alterations in AST, ALT, and GGT associated with ADR in
these personalized conditions. The ﬁndings from this ana-
lysis of clinical courses of PTB patients will help the Anti-
TB Centre to establish preventive measures for elevated liver
enzymes and the background of oxidative stress activity anti-
TB therapy.
2.MaterialsandMethods
2.1. Study Design. This study was approved by the local
Research Ethics committee of the Faculty of Health Sciences
of the Marien Ngouabi University of Brazzaville, Republic of
Congo. The study was a followup prospectively undertaken
according to the Helsinki Declaration after verbal consent
was obtained from adult patients referred to the Anti-TB
CentreinBrazzaville,RepublicofCongo,CentralAfrica,bet-
ween September 2003 and September 2004.
Inclusion criteria into the study included typical symp-
toms and signs of active PTB: chronic cough, chronic fever,
sweating, ﬁbrocavitary lung inﬁltrate on chest radiograph,
and at least one sputum specimen staining positive Ziehl-
Neelsen for acid fast bacilli. Diagnosis of PTB was based
on the WHO criteria including a positive culture for Myco-
bacterium tuberculosis or negative culture associated with
clinical and radiological features and response to treatment
consistent with TB or histological studies [16].
Exclusion criteria were age <18 years old, age >50 years
old, the conditions related to the high risk of anti-TB drug-
induced hepatitis [7, 9, 11, 12], cigarette smoking, history of
drug usage, blood transfusion previous, treatment for PTB,
coexisting lung pathology, renal failure, diabetes mellitus,
suspected multidrug resistant (MDR) and extensively drug
resistant (XDR) TB, and additional criteria for women being
pregnant or lactating, or females being menstruating at the
time of blood collection.
Based on WHO recommended standard [16], patients
received a regimen of isoniazid, rifampicin, pyrazinamide,
and ethambutol for initial phase, followed by isoniazid and
rifampicin at continuation phase. Approximately 10mL of
venous blood was drawn using disposable plastic syringes
from PTB patients prior to initiation of anti-TB therapy
(time 0 day) and at the ends of ﬁrst month (time 30 days)
and the second month (time 60 days) of the initial phase,
and transferred immediately into disposable plain tubes.
2.2.LaboratoryAnalyses. Venousbloodwasalsodrawnatthe
end of the continuation phase, and at 15 days and 45 days
after the end of the continuation phase. The serum was
separated after centrifugation of the blood and kept frozen
at −20◦C before being analyzed at the National Laboratory
of Public Health in Brazzaville, Republic of Congo.
Serum AST was evaluated by a kinetic determination.
Malate dehydrogenase catalyzes the reaction of oxaloacetic
acid with β-NADH2 by forming lactic acid and β-NAD.
SerumALTwasevaluatedbyakinetic determination.Lactate
dehydrogenase catalyzes the reaction of pyruvic acid with
β-NADH2 by forming lactic acid and β-NAD. Serum GGT
was evaluated by an enzymatic colorimetric method. All
laboratorymeasurementswereperformedusingBiom´ erieux
reagents and automatic analyzer (Visual, Biom´ eri e u x ,M a r c y
l’Etoile, France).
The interassay coeﬃcients of variation of these labora-
tory measurements were as follows: AST: 0.8%; ALT: 0.5%;
GGT: 0.6%. The intraassay coeﬃcients of variation were
within the 0.87–2.1% interval.
2.3. Monitoring. Also the participants were followed clini-
cally during anti-TB therapy course. Noxious or unintended
response to a drug which occurs at doses often used in
human beings [16]w a sr e p o r t e d .
2.4. Statistical Analysis. The data of the study were expressed
as mean ± standard deviation for continuous variables and
as proportions (%) for categorical variables.
One-way analysis of variance (ANOVA) with Bonferroni
post hoc test for multiple comparisons was used to compare
AST,ALT,andGGTmeansacrosstheperiodsoftheinitiation
phase (day 0, day 30, and day 60) and those of the continu-
ation phase (at the end of treatment, 15 days and 45 days
after the end of the continuation phase). Students t-test
served to compare the means of liver enzymes before anti-
TB treatment and the average of their means after the end of
the global treatment. Linear-by-linear association with P for
trend served to compare the proportions of ADR across the
quintiles of AST, ALT, and GGT.
Simplecoeﬃcients“r”weredeterminedbetweentheliver
enzymes, while the multiple linear regression was ﬁtted
with GGT as dependent variable and Age, AST, and ALT asAdvances in Pharmacological Sciences 3
independent variables for the mean values from the baseline
and the end of the initial phase, at the end of 30 days (1
month) and 60 days (2 months) after the ignition of the
anti-TB therapy. The assumptions were tested by the residual
analysis (diﬀerence between the actual and the predicted
score): histogram of residuals dependent variable residuals
against independent variables, and normal probability. A
P value<0.05 was considered to be statistically signiﬁcant.
SPSSforWindowsversion19.0(SPSSInc.,Chicago,IL,USA)
was used for all analyses of data.
3. Results
3.1.CharacteristicsoftheStudyPopulation. Thestudysample
comprised of 40 patients (52.5% n = 21 were males, and
47.5% n = 19 were females with sex ratio almost 1 man: 1
woman and aged 34.7 ±5.8y e a r s ) .
3.2. ADR. At the day 30 after starting the initial phase, 1
patient(3%)experiencedpruritusduetoself-administration
of 2 tablets of cotrimoxazole. His transient mild hepatic dys-
function deﬁned by a peak of serum enzymes (AST, ALT, and
GGT greater than two times of the upper limit of their
normal range: AST < 26UI/L, ALT < UI/L, and GGT = 7–
34UI/L),vomiting,diarrhoea,butwithoutjaundice.Because
normalisation of the liver enzymes and the relief of pruritus
and gastrointestinal symptoms occurred after two-day anti-
histaminic treatment, the anti-TB drugs were not stopped.
However, the day 30 liver enzymes values of this patient were
not considered in the all statistical analyses.
3.3. Variations of Liver Enzymes. The mean values of
AST (19.5 ± 8.6UI/L), AL T (7.6 ± 3.2UI/L), and GGT
(20.4 ± 16.8UI/L) before anti-TB therapy were not diﬀerent
(ANOVA, P>0.05) from those observed at the end of the
continuation phase (AST = 19.4 ± 8.5UI/L; ALT = 7.5 ±
3.5UI/L; GGT = 20.3 ± 16.8UI/L), at day 15 after the end
of the continuation phase (AST = 19.2 ± 5.8UI/L; ALT =
9.3 ± 4UI/L; GGT = 19.7 ± 12.1UI/L), and at day 45 after
the end continuation phase (AST = 19.5 ± 7.3UI/L; ALT =
11.6 ±4.7UI/L; GGT = 21.6 ±17.7UI/L).
However, during the two months of the initial phase of
anti-TB therapy, values of AST (SD: 3.1 VI/L day 0; 0.1UI/L
day 30; 5.4UI/L day 60) increased signiﬁcantly (ANOVA,
P<0.0001) across the time, while GGT values (SD: 2.8UI/L
day 0; 5.3UI/L day 30; 4UI/L day 60) decreased signiﬁ-
cantly across the time (ANOVA, P<0.0001), respectively,
(Figure 1).
At each time of the initial phase of anti-TB therapy, a sig-
niﬁcant and positive correlation between liver enzymes was
observed (Table 1). The level and the strength of association
between GGT and AST was increasing with anti-TB therapy
duration. The highest level of association between GGT and
ALT, and that between AST and ALT, was observed at day
30 after the starting of the initial phase. During the initial
phaseofanti-TBtherapyandafteradjustingforconfounding
factors (age, sex, either AST or ALT) and identifying the
independent determinants of GGT at each assessment time,
Table 1: Simple correlation coeﬃcients r between liver enzymes
according to the initial phase therapy time.
Initial GGT ALT
Phase r coeﬃcient r coeﬃcient
Time P value P value
Day 0
AST 0.279 0.735
P = 0.041 P<0.0001
ALT 0.353 1
P = 0.013
Day 30
AST 0.397 0.964
P = 0.006 P<0.0001
ALT 0.428 1
P = 0.003
Day 60
AST 0.687 0.791
P<0.0001 P<0.0001
ALT 0.382 1
P = 0.0007
there was a signiﬁcant linear relationship between adjusted
R square deﬁning the variations of GGT and the diﬀerent
times of assessment (Table 2). At day 0 and day 30 after
anti-TB treatment, only increasing ALT was the signiﬁcant
explanatory variable of the variations of GGT. At the day 60
aftertheanti-Tbtherapy,52%ofvariationsinconcentrations
of GGT were signiﬁcantly and independently explained by
the increase in AST and the decrease in ALT levels (Figure 2).
Within day 0–day 60, average values of 19.2 ± 7.8UI/L,
14.8 ± 8.9UI/L,and13.3 ± 6.1UI/L were reported for AST,
ALT, and GGT, respectively. There was a negative and sig-
niﬁcant correlation between day 0–day 60 AST values (r =
−0.494; P<0.0001) ALT values (r =− 0.472; P<0.0001),
and GGT, respectively. However, a positive and very signi-
ﬁcant association was noticed between day 0–day 60 AST
values (r = 0.893; P<0.0001) and day 0–day 60 ALT values.
After adjusting for age, ALT, and sex, 23.8% of variations of
day 0–day 60 GGT values towards decrease were explained
by the increase in day 0–day 60 AST values (standard error
= 0.063; P<0.0001) as follows: Y (GGT) = 20.8–0.494 AST.
Figure 3 describes the curves for histogram and normal P-P
plot with day 0–day 60 GGT values as a dependent variable
and a reﬂection of the impact of the initial phase anti-
TB therapy: a multivariate and negative association between
GGT and AST.
4. Discussion
In this study, the incidence of ADR was only 3%, accidental,
transient, benign and due to self-administration of cotri-
moxazole. This rate of elevation of hepatic transaminases
was within the traditional interval [7], but lower than the
levels of 50–75% ADR reported in Eastern European and4 Advances in Pharmacological Sciences
Table 2: Multiple linear regression of GGT levels at day 0, day 30, and day 60 after starting initial phase anti-TB therapy.
Initial phase time Adjusted R2 Standardized beta Standard error P value
Time independent of test variable
Day 0
ALT 10.2% 0.353 0.328 0.025
Day 30
ALT 16.1% 0.428 0.715 0.007
Day 60 51.6%
AST 1.027 0.134 <0.0001
ALT −0.430 0.162 0.023
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Figure 1: Variations of AST, ALT, and GGT during the two months of initial phase with their Bonferroni post hoc tests. ∗Day 0 versus day
30: P<0.0001; day 0 versus day 60: P<0.0001. ∗Day 30 versus day 60: P<0.0001.
Asian countries [17]. ADR occurred within the ﬁrst 30 days
of the initiation of anti-TB treatment as usually reported by
diﬀerent studies [17, 18]. Concomitant use of cotrimoxazole
or other hepatotoxic drugs is well established as a risk factor
for anti-TB-induced liver injury [7, 9, 11, 12].
A signiﬁcant downward trend in GGT levels was ob-
served from the starting to the end of the initial phase of
DOTS.This is becausethe initial two-month therapy leads to
signiﬁcant improvement in oxidative stress and suppression
of inﬂammation determined by active PTB [2, 3]. Aging,
already associated with oxidative stress [19], was one of the
exclusion criteria in this study because elderly patients are
at a greater risk of oxidative stress and of hepatotoxicity
probably because of immunity mechanisms.
In PTB, neutrophils, monocytes, and macrophages are,
mobilized to destroy Mycobacteria and generate huge
amounts of ROS and lipid peroxidation [20–22] .As e r i e so f
data obtained from black and white men suggest that serumAdvances in Pharmacological Sciences 5
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Figure 2: Multivariate relation between AST (a), ALT (b), and GGT at day 60 of initial phase of DOTS.
GGT within its normal range might be an early marker of
oxidative stress [13]. The variations of serum GGT in this
study, except in one patient with benign ADR, were within
their normal range before and after DOTS. The deﬁciency of
antioxidants renders PTB patients unable to cope with their
increased oxidative stress [21].
With progressive DOTS during the two months of the
initial phase, the baseline relationship between GGT and
AST, as well between GGT and ALT changed, respectively.
The relationship between GGT and ALT become not signiﬁ-
cant in considering their average values of day 0–day 60. This
means that the anti-TB might neutralise the baseline (day 0,
day 30, and day 60) synergistic action of GGT and ALT, both
markers of oxidative stress [15]. However, in considering the
day 0–day 60 average of liver enzymes, only AST was nega-
tively, signiﬁcantly and independently associated with serum
GGT in these black PTB patients.
5. ClinicalImplications
The present study will have signiﬁcant implications in un-
derstanding the role of oxidative stress biomarkers and that
of liver enzymes in personalizing the DOTS. Systematic steps
for prevention of hepatotoxicity are recommended in anti-
TB therapy. These recommendations include patient and
regimen selection to optimise beneﬁts over risks. Education
of patients to avoid self-administration of medications inter-
fering with anti-TB drugs is mandatory.
During the ﬁrst two months of anti-TB therapy, ALT,
AST, and GGT monitoring is recommended. If serum GGT
is a marker of oxidative stress targeted by anti-TB during the
initial phase, it might have important implications both clin-
ically and epidemiologically because measurement of serum
GGT is easy, reliable, and not expensive. It is important to
evaluate in tuberculosis patients on DOTS intake of fruits
and vegetables, which are rich in antioxidants. Particular
attention must be paid in elderly patients at a greater risk of
toxicity because of potential poor antioxidant mechanisms
[3, 23].
The oxidative stress due to PTB and aggravated by anti-
TB therapy hepatotoxicity and the severity of PTB could be
reduced by adjuvant therapy with dietary phytochemicals
and antioxidants [24, 25].
5.1. Limitations of the Study. The study was limited to some
degree, as monitoring of AST, ALT, and GGT was not per-
formed monthly from the end of the initial phase and the
end of the continuation phase.
6. Conclusion
This study concludes that oxidative stress markers within
normal range before starting anti-TB treatment and con-
sidering conditions related to hepatotoxicity in patients ad-
mitted for active PTB might predict excellent tolerability of
anti-TB drugs and very low rate of ADR.6 Advances in Pharmacological Sciences
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Figure 3: Frequency distribution by histogram (a) and normal P-P plot of regression-standardized residual (b) for GGT as dependent
variable and AST as the only independent determinant (c) during day 0–day 60 anti-TB therapy of initial phase.
ThedecreaseinserumGGT,contrastingwiththeincrease
in serum AST and ALT, should reﬂect the eﬀect of anti-TB
therapy during the intensive and initial two-month phase of
DOTS. Cotrimoxazole induces a transient enhancement of
oxidative stressdue to tuberculosis itself and anti-TB chemo-
therapy.
Clinicians should educate patients about risk factors of
anti-TB treatment-induced hepatotoxicity as well as they
should be vigilant for conditions related to oxidative stress
and deﬁciency of antioxidant systems.
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